Clinical Trial Detail

NCT ID NCT03098836
Title Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Daniel George, MD
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Apalutamide + Prednisone

Age Groups: adult senior

No variant requirements are available.